Abstract
Data on risks of development of oncological diseases of bodies of reproductive system in women during menopausal transition and in a postmenopause are submitted at treatment of menopausal frustration by the preparations intended for menopausal hormonal therapy, the containing various doses of estrogen and progestogen used in the cyclic or continuous mode.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.